Introduction
ATP binding cassette (ABC) transporters at the blood-brain barrier (BBB) prevent the entry of unwanted endogenous signalling molecules and toxic xenobiotics from the blood into the brain [reviewed in (Loscher and Potschka, 2005) ]. To date, at least 48 ABC transporter genes have been identified and are classified into seven subfamilies, denoted ABCA to ABCG (Dean et al., 2001; Higgins, 1992) . ABCB1/MDR1 [(P-glycoprotein (P-gp)] is the most extensively studied ABC transporter at the BBB, both in vitro and in vivo, and prevents a broad range of substances from entering brain tissue, including many therapeutic drugs in use today such as anti-epileptics, anti-cancer drugs and HIV protease inhibitors [reviewed in (Loscher & Potschka 2005 , Schinkel 1999 , Zhou 2008 ].
Structurally, P-gp is arranged into two halves connected by a 75 amino acid linker region, with each half consisting of a transmembrane domain (made of 6 transmembrane segments), an intracellular nucleotide-binding domain and both the N and carboxyl termini, which are located intracellularly (Linton, 2007; Schinkel, 1999; Schinkel and Jonker, 2003) . Conflicting evidence exists as to the expression of P-gp by brain endothelial cells (BECs). P-gp expression has been described on the luminal membrane of rat brain capillaries (Beaulieu et al. 1997 , Miller et al. 2000 , isolated mouse brain endothelial cells (Tatsuta et al., 1992) , and human brain microvessels (Seetharaman et al. 1998 , Virgintino et al. 2002 . In contrast, enhanced abluminal expression of P-gp has been observed in rat BECs using transmission electron microscopy (EM) techniques (Bendayan et al., 2006) . Nevertheless, it is widely accepted that P-gp expression is primarily located on the luminal membrane of BECs.
Whilst multiple studies have been carried out to identify the characteristics of P-gp substrates, the most common feature is their hydrophobic nature, which allows A C C E P T E D M A N U S C R I P T
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them to diffuse across the lipid bilayer relatively easily (Cabrera et al., 2006; Cianchetta et al., 2005; Crivori et al., 2006; Penzotti et al., 2002; Wang et al., 2003) .
Indeed, P-gp has been hypothesised to act as a flippase transporter (Schinkel, 1999) .
In vivo data supports the notion of a barrier function for P-gp at the BBB. Mice, lacking either mdr1a or combined mdr1a/b genes (equivalent to human ABCB1), display enhanced brain accumulation of many P-gp substrates including verapamil, indinavir, vinblastine and morphine, when compared to wild type control mice [reviewed in (Loscher & Potschka 2005 , Miller et al. 2008 , Schinkel 1999 ]. In addition, P-gp inhibition in rats results in increased brain concentrations of colchicine and vinblastine (Drion et al., 1996) .
In vivo studies represent an important data source for evaluation of ABC transporter function at the BBB, but they are highly costly and extrapolation from animal models to humans may be problematic due to species differences. For routine investigations into P-gp function by human BECs in vitro, there are currently two choices, primary and immortalised human BECs. Human primary cell cultures are not readily available and, in our experience, do not remain stable over ~ 5 passages, and are therefore not suited for routine medium/high throughput studies. hCMEC/D3 cells represent the most extensively characterized immortalised human BEC line to date, and retain a BEC typical phenotype (Weksler et al. 2005) . hCMEC/D3 cells express tight junctional proteins and are restrictive to molecules larger than 4 kDa in molecular weight, in agreement with in vivo studies (Weksler et al. 2005) . Previously, P-gp expression by hCMEC/D3 cells has been demonstrated using western blotting and mRNA analysis (Weksler et al. 2005 ). In the same study, an increase in the net influx of rhodamine 123 (rh123) was reported following inhibition of P-gp with PSC-
833, demonstrating that the transporter was indeed functional, as confirmed in a recent study (Poller et al., 2008) .
The aim of this study was to further examine P-gp expression and function in hCMEC/D3 cells to determine their suitability as an in vitro human BBB model for identifying potential P-gp substrates. We first investigated P-gp expression by hCMEC/D3 cells, including its subcellular localisation and polarisation, and compared it to that of primary human BECs. P-gp functionality in hCMEC/D3 cells and primary human BECs was then investigated using rhodamine 123 (rh123) efflux, with the 3 rd generation P-gp inhibitor tariquidar, or the P-gp competitive substrate vinblastine. Finally, using P-gp inhibitors, we investigated the permeability of hCMEC/D3 cells to rh123 in order to confirm polarised P-gp function.
Results

P-gp expression by hCMEC/D3 cells is stable and comparable to that of primary human brain endothelial cells
The levels of P-gp expression were compared between hCMEC/D3 cells at early passages (between 23 and 28) and primary human BECs (between 2 and 3) to determine the suitability of the cell line as an in vitro human BBB model ( Fig. 1 ).
Both primary human BECs and hCMEC/D3 cells expressed P-gp as demonstrated by a higher median fluorescence staining intensity compared to their negative controls ( Fig. 1a ). The levels of P-gp expression by primary human BECs were 30 % higher than those expressed by hCMEC/D3 cells, although this difference was not statistically significantly different [ Fig. 1c , (p = 0.065)]. These results indicate that the level of expression of P-gp by hCMEC/D3 cells is close to that of primary human
BECs.
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The expression of P-gp by hCMEC/D3 cells over increasing passage (p) number was assessed in order to investigate stability of phenotype by this cell line (Figs. 1b and c) . Using western blotting techniques, P-gp expression was detected as a diffuse band of ~ 160 kDa, reflecting different glycosylation patterns of the ABCB1 product (Ichikawa et al., 1991) . P-gp expression was stable between p23 and p38, but appeared to decline at higher passages. In contrast, actin levels were maintained with the exception of the highest passage investigated (p44), whereas for P-gp expression, they declined. When normalised to actin, P-gp was stable up to p38 and decreased by ~ 35 %, between p38 and p41 ( Fig. 1c ).
Distribution of P-gp expression by hCMEC/D3 cells
We next investigated the sub-cellular localisation of P-gp expression by hCMEC/D3 cells. Using fluorescence microscopy, P-gp was not detected in the nucleus but appeared to be distributed throughout the cytoplasm and plasma membrane ( Fig. 2) . A cellular fractionation assay was then employed to investigate the relative sub-cellular distribution of P-gp. hCMEC/D3 cells were separated into cytosolic, membrane/organelle, nuclear and cytoskeletal fractions using differential detergent fractionation ( Fig. 3a & b ). Sp3, a transcription factor, was detected almost entirely in the nuclear fraction, whereas actin was expressed highest in the cytoskeletal fraction followed by nuclear and membrane fractions. P-gp was predominantly, although not exclusively, expressed in the membrane/organelle fraction. These results indicate that in hCMEC/D3 cells, P-gp is located on cellular membranes, which includes both the plasma membrane and membranes of intracellular organelles, in hCMEC/D3 cells.
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P-gp expression is polarised to the apical membrane of hCMEC/D3 cells
P-gp expression was then investigated by transmission EM combined with
immunogold staining (Fig. 4a , b & c), to determine its subcellular localisation.
Immunolabelling was detected both in the cytoplasm and on the plasma membrane (with a distribution pattern of 43 %, and 57 %, respectively). However, the number of gold particles associated with the apical plasma membrane was nearly 3 times greater than that on the basolateral membrane ( Fig. 4d, 66 images analysed over a 500 μm section of membrane). Therefore, whilst P-gp molecules appear distributed on both membranes and in the cytoplasm, the majority of plasma membrane P-gp was on the apical membrane, which is consistent with the blood side in vivo. The localisation of P-gp to the apical plasma membrane of hCMEC/D3 cells suggests that this transporter may act to prevent the movement of P-gp substrates from the apical to the basolateral compartments in in vitro permeability studies.
P-gp mediates rhodamine 123 efflux by hCMEC/D3 cells
Using non-cytotoxic concentrations of the P-gp inhibitors tariquidar or vinblastine, or the Breast Cancer Resistance Protein (BCRP) inhibitor fumitremorgin c (FTC) (data not shown), rh123 efflux from preloaded hCMEC/D3 cells was investigated as a means to determine P-gp functionality in this cell line. rh123 efflux is potentially a more sensitive measure of P-gp activity than net rh123 influx, since it is exclusively dependent on the efflux activity of P-gp rather than a measure of the relative contribution of efflux versus influx mechanisms. Compared to cells preloaded with rh123 and incubated at 4 o C, cellular levels of rh123 decreased sharply within 1 h and continued to decline thereafter. The t 1/2 for rh123 efflux was estimated to be 13. with 22 μM rh123 at 4 o C for 60 min, and incubated at 37 o C for 60 min (Fig. 5b ). In addition, P-gp function in hCMEC/D3 cells was comparable to that obtained using primary hBECs over a 15 min efflux assay ( Fig. 5c ). These results demonstrate that rh123 efflux from hCMEC/D3 cells is largely mediated by P-gp.
Tariquidar has been demonstrated to have a long-lasting, possible irreversible, inhibitory effect on P-gp (Mistry et al., 2001) , whilst vinblastine acts as a competitive inhibitor. To investigate the mechanism of P-gp inhibition by tariquidar and vinblastine, hCMEC/D3 cells were pre-loaded at 4 confirm previous studies that tariquidar is a long lasting P-gp inhibitor which, unlike -8 -
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vinblastine, can exert its effect after removal from the culture medium (Mistry et al., 2001) .
P-gp restricts the apical-to-basolateral permeability of hCMEC/D3 cells to rh123
Since; 1) P-gp appeared polarised on the apical membrane of hCMEC/D3 cells, and 2) rh123 was a suitable substrate to measure P-gp function using an efflux assay, we next investigated the permeability of hCMEC/D3 cells in a two-dimensional assay, to rh123, as a guide to polarised functionality (Fig. 6 ). The P-gp inhibitors vinblastine and tariquidar did not significantly affect the basolateral-to-apical permeability of hCMEC/D3 cells to rh123 (n = 3 P > 0.05). However, tariquidar and vinblastine both increased hCMEC/D3 cell apical-to-basolateral permeability to rh123 by 67% and 55 % respectively, compared to control levels (n = 3 P < 0.05). These results imply that P-gp, located on the apical membrane, restricts the transport of rh123 in the apical-to-basolateral direction.
Discussion
Human BECs express P-gp, which acts as a barrier for many therapeutic drugs and endogenous molecules, preventing their entry into the brain [reviewed in (Loscher & Potschka 2005 , Schinkel 1999 ]. The study of P-gp in vitro using human BECs is valuable for identifying potential substrates and inhibitors. The data presented here show, that the immortalised human BEC cell line, hCMEC/D3, expresses P-gp when assessed by flow cytometry, western blotting, immunocytochemistry and immunoelectron microscopy. These data are in agreement with numerous studies that have demonstrated BEC P-gp expression at both the protein and mRNA level using in vitro
ACCEPTED MANUSCRIPT
cultures of both primary and immortalised cells of rat, mouse and human origin (Beaulieu et al., 1997; Begley et al., 1996; Miller et al., 2000; Perriere et al., 2007; Seetharaman et al., 1998; Tatsuta et al., 1992; Virgintino et al., 2002) . In terms of Pgp expression, the BEC phenotype appears to be preserved in hCMEC/D3 cells over a wide range of passages, and P-gp expression was comparable to cultured primary BECs, albeit slightly reduced. It is possible, however, that the cultured primary BECs used here have lower P-gp expression compared to isolated capillaries, which as demonstrated in rat and humans, more closely mimic the in vivo situation (Barrand et al., 1995; Regina et al., 1998; Regina et al., 1999; Seetharaman et al., 1998) . Our observations are in agreement with those of Regina and co-workers, who reported lower expression of P-gp by an immortalised rat BEC cell line, RBE4, compared to primary rat BECs (Regina et al., 1998; Regina et al., 1999) . None-the-less, the small difference in P-gp expression between for primary BECs and hCMEC/D3 cells did not result in measurable differences in P-gp function. The limited availability and stability of primary human cells, and the species differences between rat and human, makes hCMEC/D3 cells an attractive option for the study of P-gp function and identification of potential substrates over a large passage range.
In this study, differential detergent fractionation of hCMEC/D3 cells showed that P-gp expression was localised to the membrane/organelle fraction. Using transmission EM and immunogold staining, P-gp was found to be localised mainly in or at the apical membrane, although labelling in the cytoplasm and in the basolateral membrane was also observed. Using EM techniques, we found ~40 % P-gp expression in the cytoplasm of hCMEC/D3 cells , an observation that may reflect an intracellular P-gp pool capable of plasma membrane translocation under certain conditions. Indeed, some immunolabelling appeared localized to intracellular vesicles Fig. 4a ). However, it is also possible that the intracellular P-gp staining represents internalised P-gp targeted for degradation, or newly synthesised P-gp in transit towards the plasma membrane.
These results are in partial agreement with studies from rat brain tissue, (Bendayan et al. 2006) this study, might reflect species differences between rats and humans. The antibody C219 recognises P-gp epitopes that differ slightly between rats and humans, with potentially a higher affinity for the rodent N-terminal domain (Georges et al., 1990) . been observed in isolated human brain capillaries (Seetharaman et al., 1998) , human tissue (Virgintino et al., 2002) , and isolated capillaries from rats (Beaulieu et al., 1997; Miller et al., 2000) . The differing results of Bendayan et al to those of others in the field, including the present study, might relate to the method of fixation.
Manoonkitiwongsa et al (Manoonkitiwongsa et al., 2000) have demonstrated that for Na + , K + ATPase staining, with an increasing concentration of fixative (that has deleterious effects on antibody recognition), the staining decreased to a greater degree on the luminal than abluminal side. Therefore, it is possible that, when brain tissue -11 - The results presented here also confirm functional P-gp expression by hCMEC/D3 cells. The t 1/2 obtained here for rh123 efflux (~13 min) is in agreement with another study that found a t 1/2 of similar magnitude in rat primary BECs (~ 10 min) (Ji et al., 2005) . However, in contrast to the relatively modest increase in the efflux t 1/2 caused by another competitive inhibitor, verapamil, in that study (t 1/2 ~ 20 min), in the present study vinblastine caused a much more potent inhibition (t 1/2 ~ 110 min). Several factors may contribute to the differences in P-gp inhibition between this study and the one by Ji et al: 1) differences in P-gp expression levels between rat and hCMEC/D3 cells; 2) levels of ATP in the culture media; 3) differences in the method employed for rh123 efflux. With regards to the latter, Ji et al preloaded rat BECs at 37 o C rather than 4 o C as used in this current study and the data were expressed as a percentage of time zero. However, rh123 cellular levels at 37 o C would be influenced not only by passive diffusion, but also by active efflux transport making interpretation of results difficult. Since vinblastine and tariquidar both inhibited efflux of rh123, there is strong evidence that rh123 efflux from hCMEC/D3 cells is largely mediated by P-gp.
In agreement with other studies, FTC, a BCRP inhibitor, did not inhibit rh123 efflux (Weksler et al., 2005; Zhang et al., 2003) . BCRP has been demonstrated to use rh123 as a substrate only when there is a mutation at position 482, characteristic of tumour cells (Alqawi et al., 2004; Sarkadi et al., 2004) . Therefore, it is likely that hCMEC/D3 cells express wild type, non-mutated BCRP, since BCRP activity has
previously been demonstrated in hCMEC/D3 cells (Weksler et al. 2005 ). In addition, the inhibition of P-gp function by tariquidar was longer-lasting than that of vinblastine. This observation is in agreement with Mistry et al (Mistry et al., 2001) , who reported a long-lasting inhibition of rh123 and 3 H-daunorubicin efflux by tariquidar in a human ovarian carcinoma cell line, even if the inhibitor was only present in the pre-loading stage. This evidence suggests that tariquidar might be a more suitable inhibitor than vinblastine for the study of the role of P-gp in the penetration of the CNS by drugs.
Using a more relevant model of BBB transport, whereby hCMEC/D3 cells are grown on filters, we have demonstrated that P-gp restricts the apical-to-basolateral permeability of hCMEC cells to rh123. These data support our observation that P-gp appears localised to the apical plasma membrane in hCMEC/D3 cells as assessed by EM techniques and immunogold staining. In agreement, we have also recently reported that P-gp restricts the apical-to-basolateral, but not basolateral-to-apical, permeability of hCMEC/D3 cells to Aβ 1-40 (Tai et al., 2009) . The restriction in apical-to-basolateral permeability that P-gp affords to BECs in vitro is consistent with the observation that, in vivo, mdr1a or mdr1a/b knock-out mice display enhanced CNS accumulation of many P-gp substrates, including cyclosporin A, vinblastine, digoxin, morphine and digoxin, colchicine and morphine [reviewed in (Loscher & Potschka 2005 , Schinkel 1999 ]. The polarised nature of P-gp function has been demonstrated in vitro on isolated BECs grown on filter inserts, which show directional transport of cyclosporin A and vincristine in mouse BECs (Shirai et al., 1994; Tatsuta et al., 1992) .
In summary, functional P-gp expression has been demonstrated in the human immortalised cell line, hCMEC/D3. Importantly, hCMEC/D3 cells express P-gp
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polarised on the apical membrane, which restricts endothelial permeability to rh123 in the apical-to-basolateral direction.
Experimental procedures
Materials
Tariquidar was a kind gift from Xenova (Slough, Berkshire, UK), Fumetrimorgan C (FTC) was from Axxora (Nottingham, Nottinghamshire, UK).
Tissue culture plastic was from Greiner (Gloustershire, UK). All other reagents were from Sigma-Aldrich (Gillingham, Dorset, UK) unless stated.
Isolation of human brain endothelial cells
In procedures approved by both Kings College London and The Open
University local ethical committee guidelines (Protocol 99-002), human brain tissue was obtained with written consent from patients undergoing cerebral cortical lobectomies, conducted at Kings College Hospital to relieve medically intractable seizures. The isolation of human BECs was carried out as described by Weksler et al (Weksler et al. 2005 
A C C E P T E D M A N U S C R I P T
ACCEPTED MANUSCRIPT endothelial cells, puromycin (0.5 μg/ml) was added to the culture medium for the first three days following isolation.
Cell culture
hCMEC/D3 and primary human BECs were cultured in EGM-2 medium (Lonza, Slough, Wokingham, UK) supplemented with VEGF, IGF, bFGF, hydrocortisone, ascorbate, gentamycin and 2.5 % fetal bovine serum (FBS) as indicated by the manufacturer. Cells were grown on collagen-coated (5 mg/ml, 1h
RT) tissue culture plastic in a humidified atmosphere at 37 o C in 5 % CO 2 . For all experiments, BECs were grown to confluence and left for 2 days prior to treatment (~ 1 x 10 5 cells / cm 2 ), with the EGM-2 medium changed every 2-3 days. 
Western blotting
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0.0625 M Tris pH 6.8, 0.008 % (v/v) β-mecaptoethanol] and re-probed with mouse monoclonal anti-actin (1 μg/ml). The signal intensities of the bands were then normalised to actin.
Differential detergent fractionation
hCMEC/D3 whole cell lysates were separated into cytosolic, membrane/organelle, nuclear and cytoskeletal fractions using differential detergent fractionation as described by Ramsby et al (Ramsby et al., 1994) . subjected to electrophoresis and immunoblotting as described above.
Flow cytometry
Fully confluent hCMEC/D3 and primary BECs were detached as described 
Immunocytochemistry
hCMEC/D3 cells were grown to fully confluence on collagen coated glass coverslips (5 mg/ml, 1 h). Cells were then fixed in methanol at -20 o C for 10 min, and washed 3 times in PBS. An anti-P-gp antibody (Table 1) 
Transmission electron microscopy combined with immunogold labelling
For the detection of P-gp at the ultrastructural level, the method of Bendayan et al (Bendayan et al., 2006) was followed with modifications. Briefly, hCMEC/D3 cells were grown to confluence on collagen-and fibronectin-coated transwell polyester membrane inserts and left for 2 days. hCMEC/D3 cells were then fixed for Ultrathin 80 nm sections of the membrane insert were then cut using a Diatome diamond knife on a Leica ultra-microtome (Leica UCT, Leica, Buckinghamshire UK).
The sections were mounted on formvar (Agar Scientific, Stanstead, Essex, UK) coated nickel slot grids. Non-specific binding was blocked using 1 % (w/v) ovalbumin in 0.01 M PBS for 30 min at RT. Grids were incubated with droplets of an anti-P-gp antibody (Table 1) 
